Bioavailability and Pharmacokinetics of 50 mg BI 135585 XX Administered as Tablet With and Without Food in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)

Trial Profile

Bioavailability and Pharmacokinetics of 50 mg BI 135585 XX Administered as Tablet With and Without Food in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs BI 135585 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Apr 2011 Status changed from recruiting to completed, according to ClinicalTrials.gov.
    • 10 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top